← All Akari Therapeutics PLC filings

Akari Therapeutics PLC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
AKTX
Akari Therapeutics PLC
10-K: Akari Therapeutics Focuses on Oncology Pipeline After Merger, Outlines Financial Risks in 10-K Filing
Akari Therapeutics shifts focus to oncology with its ADC platform following a merger, while acknowledging significant financial risks and material weaknesses in internal controls in its recent 10-K filing.
NASDAQ
AKTX
Akari Therapeutics PLC
10-K: Akari Therapeutics Outlines Share Structure and Rights in SEC Filing
Akari Therapeutics, Plc details the rights and characteristics of its ordinary shares and American Depositary Shares (ADSs) in a recent SEC filing.